Pharmaceutical Executive March 18, 2025
Dr. Dina Radenkovic, CEO of Gameto, identifies strategies to close the gap in women’s health and how we can better incentivize research and development in this area.
In this Pharmaceutical Executive video interview, Dr. Dina Radenkovic, CEO of Gameto, discusses the company’s pioneering use of induced pluripotent stem cell (iPSC) technology in fertility treatments, particularly addressing ovarian aging. Its lead product, Fertilo, is an iPSC-derived ovarian support cell line in phase III clinical trials in the US with FDA clearance, and commercial availability in markets like Australia and Latin America. The company faces challenges including the scarcity of human eggs and regulatory hurdles. Radenkovic also highlights the need for better models to study female-specific conditions and the importance of political...
Today's Sponsors
Today's Sponsor